Loading
A phase 3 trial of Sonrotoclax, Obinutuzumab, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) is a phase 3 interventional study registered as NCT06943872 by BeOne Medicines, with 630 participants planned, started 2025-06-11 and due to reach its primary completion in 2029-09-30. Interventions recorded: Sonrotoclax, Obinutuzumab, Rituximab and Venetoclax.
Shares Sonrotoclax, BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Venetoclax, Rituximab and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.